Health Canada Approves Daybue!

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome.

DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder. We recognize the incredible sacrifices made by individuals with Rett syndrome and their families who participated in the clinical trials. Thanks to their courage, along with the dedication and perseverance of Acadia Pharmaceuticals, we have reached a pivotal milestone for Canadian families. We are grateful to everyone involved in making this treatment a reality today.
Consult your healthcare provider to learn more and determine if Daybue is suitable for your loved one. Your family doctor, pediatrician, Rett syndrome specialist, or neurologist can assist with enrollment by visiting www.acadiaconnect.com. 

Click Here for Official Press Release